The European Haemophilia Consortium (EHC) is an international non-profit organisation representing 48 national patients’ organisations for people with rare bleeding disorders from 27 Member States of the European Union (EU) and most Member States of the Council of Europe.
The EHC represents approximately 90,000 people diagnosed with a rare bleeding conditions such as haemophilia, von Willebrand Disease (VWD) and other rare bleeding disorders across Europe. However, experts estimate that many more live with an undiagnosed rare bleeding disorder.
The EHC actively supports its National Member Organisations (NMOs) at national and European levels and also helps NMOs to engage with each other, with the objectives of:
- Improving the quality of life of people living with rare bleeding disorders;
- Improving diagnostic and treatment facilities;
- Ensuring the adequate supply of – and access to – safe therapies;
- Promoting patients’ rights and raising ethical issues;
- Following and influencing developments in European health policy;
- Understanding the status of treatment and care in member countries through regular surveys;
- Stimulating research in all fields related to haemophilia and related rare bleeding disorders.
The EHC draws on the knowledge of patients, healthcare professionals, the scientific community, the European institutions and the pharmaceutical industry to share expertise within Europe. The EHC also collaborates closely with other European patient organisations to ensure a strong collective voice for people with rare bleeding disorders.
Disclaimers
The name “European Haemophilia Consortium (EHC)” and the EHC logo are the exclusive property of the European Haemophilia Consortium. Any use of the name or logo must receive prior approval from the EHC Steering Committee. The use of the EHC name and/or the EHC logo is only allowed when the content of the publication is reviewed and approved by the EHC. This rule entails all forms of publication, including print and digital formats. Reprinting, redistribution, or translation of any EHC publication is subject to the permission request.
Requests for review and approval should be submitted to the EHC Communications Team at [email protected] in a timely manner.
Please note: Information and materials on this website are intended for general information only. The EHC does not endorse or promote any specific pharmaceutical organisation, drug or other medical intervention; any reference to a product name is not an endorsement by the EHC.
For any inquiries or additional information, please contact the Communications Team at the email address provided above. If you find any inaccuracies on the website, please report them to us.
Jim is aged 66 and has Haemophilia A with a high titer inhibitor which he developed at age 14.
Maria Elisa Mancuso (MD, PhD) is a Haematologist and works as a Senior Haematology Consultant at the Center for Thrombosis and Haemorrhagic Diseases of IRCCS Humanitas Research Hospital in Rozzano, Milan, Italy. She is Adjunct Clinical Professor at Humanitas University. She obtained a post-degree in Clinical and Experimental Haematology and a PhD in Clinical Methodology. She is involved in clinical research and has published several original articles in peer-reviewed journals a The Lancet, Blood, Journal of Thrombosis and Haemostasis, Haematologica, Thrombosis and Haemostasis, British Journal of Haematology and Haemophilia. She is reviewer for several peer-reviewed journals and member of the Editorial Board of JTH. She is a member of several scientific societies (ISTH, WFH, ASH, EAHAD, SISET, AICE) and was a medical member of the Inhibitor Working Group of the European Hemophilia Consortium. She is co-chair of the ADVANCE Study Group. She has acted also as co-chair of the Scientific and Standardization Subcommittee of ISTH on FVIII, FIX and rare bleeding disorders. She has been involved as principal and co-investigator in several clinical trials, and she takes care of both children and adults with hemophilia and other congenital bleeding disorders with a specific scientific interest in novel therapies, prophylaxis, inhibitors, and chronic hepatitis C.
As a patient with factor II deficiency, the diagnostic and treatment of rare bleeding disorders is a matter dear to my heart. My motivation to participate in the work of the ERIN committee is to improve both diagnostic and treatment for patients with rare bleeding disorders across Europe.
Economist and financial expert by profession, executive coach and trainer by passion and haemophilia advocate by every drop of my blood through my son (who has severe haemophilia A with inhibitors). Bringing a good decade of practical experience from the corporate insurance world, laser focus, growth mindset and resilience from my own experience, offering you anything I can just do, in hope that together we can make life more fulfilled for those impacted by bleeding disorders.
Amy Owen-Wyard is a Registered Mental Health Nurse. With experience working with children, young people, their families and adults with severe and enduring mental health conditions. Amy was also involved in a service improvement to provide a holistic care approach for those in general hospitals to support both their mental and physical health, whilst sharing her expertise and knowledge in mental health with the wider multidisciplinary team.
